Article
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
Alimentary pharmacology & therapeutics - 15 Aug 2008
Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli M C, Tame M R, Piscaglia F, Andreone P, Ballardini G, Bernardi M, Bianchi F B, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi G L, Grigioni W, Lorenzini S, Pinna A D, Ravaioli M, Roda E, Sama C, Vivarelli M
Abstract excerpt
BACKGROUND: Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates. AIM: To assess the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b + ribavirin (RBV) in patients with post-LT recurrent genotype-1 HCV and to establish...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.